Sun Pharma Wins Lipitor Antitrust Litigation Appeal

Sun Pharmaceutical Industries Limited and its subsidiaries have received a favorable outcome in the Lipitor antitrust litigation in the United States. The United States Court of Appeals for the Third Circuit affirmed the District Court's decision, granting summary judgment in favor of Sun Pharma and denying class certification to the plaintiffs. This ruling significantly concludes the litigation, which alleged that a patent settlement agreement unlawfully delayed generic competition for Lipitor (Atorvastatin).